Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P107 is a processed pseudogene of the ribosomal protein L21 gene in humans. Pseudogenes are typically non-functional DNA sequences that resemble known genes but do not encode functional proteins. RPL21P107 is not expressed as a protein and does not have known biological functions, disease roles, or drug interactions. It is classified as a pseudogene and does not function as an enzyme, receptor, transporter, or therapeutic target[3][5][7]. The canonical, functional gene is RPL21, which codes for a component of the 60S ribosomal subunit, essential for protein synthesis in the cytoplasm[1][2]. There are numerous ribosomal protein pseudogenes dispersed throughout the human genome, including RPL21P107[1][2].\n\nKey points:\n- This entry is a pseudogene and not a therapeutic target.\n- No known disease association, molecular activity, or drug interaction.\n- The correct molecular classification is "Other" (specifically, pseudogene).\n- The entry may be misleading if interpreted as a functional target; thus, is_incorrect: true applies for drug/discovery targeting purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L21 pseudogene 107 (RPL21P107).